Medical News

RSS

Earthy or musty odors along with cyanobacteria may indicate presence of harmful cyanotoxins in lakes

Earthy or musty odors, along with visual evidence of blue-green algae, also known as cyanobacteria, may serve as a warning that harmful cyanotoxins are present in lakes or reservoirs. In a newly published USGS study of cyanobacterial blooms in Midwest lakes, taste-and-odor compounds were found almost every time cyanotoxins were found, indicating odor may serve as a warning that harmful toxins are present.

14 Sep 2010

Researchers identify markers to predict preeclampsia risk in early pregnancy

Researchers identified 14 new markers that could identify in early pregnancy who may be at risk of developing preeclampsia in later pregnancy. An international team of scientists and physicians used a combination of sophisticated emerging technologies and data analysis to detect 14 simple metabolites with high accuracy to predict in early pregnancy which women are at risk of developing preeclampsia in later pregnancy.

14 Sep 2010

Montana to implement ACOEM's APG-I on-line practice guideline system

Montana's Department of Labor and Industry has announced that it will implement a system of Utilization and Treatment Guidelines using the on-line infrastructure and selected content provided by the American College of Occupational and Environmental Medicine (ACOEM).

14 Sep 2010

Momenta Pharmaceuticals receives patent for enoxaparin

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping".

14 Sep 2010

$Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL$

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it intends to appeal the U.S. Food and Drug Administration's previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL").

14 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

IGI submits first ANDA to FDA

IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted its first abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented "This is a significant step forward in validating IGI's commitment to pharmaceutical product development.

14 Sep 2010

BSD publishes article on technology to improve heat therapy delivery for cancer treatment

BSD Medical Corporation today reported publication of an article on BSD's pioneering development of sophisticated technology to improve the delivery of heat therapy for the treatment of certain cancerous tumors.

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

Exercise training, diet counseling for patients with heart disease risk improves quality of life

A lifestyle intervention incorporating exercise training and diet counseling in primary health care settings appears to improve quality of life among adults at moderate to high risk for heart disease and appears cost-effective compared to standard care, according to a report in the September 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

14 Sep 2010

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.

14 Sep 2010

Researchers reveal new way of restraining beta-catenin to suppress tumor metastasis

Researchers reveal a new way in which cells restrain beta-catenin and potentially suppress tumor metastasis, the protein can be ejected from cells in small vesicles called exosomes. The study appears online on September 13 in the Journal of Cell Biology.

14 Sep 2010

Enlarged hearts regress faster in elderly women than in men after aortic valve replacement

Heart enlargement caused by narrowed aortic valves regresses faster in elderly women than in men after aortic valve replacement, according to research reported in a surgical supplement of Circulation: Journal of the American Heart Association.

14 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.

14 Sep 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

New 'Therapeutic Hypothermia and Temperature Management' journal

Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal from Mary Ann Liebert, Inc., publishers, covers all aspects of hypothermia and temperature considerations relevant to this exciting field, including its application in cardiac arrest, spinal cord and traumatic brain injury, stroke, myocardial ischemia, neurogenic fever, emergency medicine, ICU management, anesthesiology, pediatrics, and much more.

14 Sep 2010

Experts warn dip in antibiotic R&D could lead to treatment challenges

The 50th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) kicked off in Boston on Sunday with experts warning that a "slowdown" in research on antibiotic development could result in treatment challenges.

14 Sep 2010

Human cytomegalovirus cloned

A team of Welsh scientists have successfully cloned a human virus offering new hope for the treatment of potentially life-threatening diseases.

14 Sep 2010

ADHD medication improves childhood cancer survivors: Research

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

14 Sep 2010

Medical News

Earthy or musty odors along with cyanobacteria may indicate presence of harmful cyanotoxins in lakes

Researchers identify markers to predict preeclampsia risk in early pregnancy

Montana to implement ACOEM's APG-I on-line practice guideline system

Momenta Pharmaceuticals receives patent for enoxaparin

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Excelimmune presents positive results for HRPA therapy against MRSA infections

IGI submits first ANDA to FDA

BSD publishes article on technology to improve heat therapy delivery for cancer treatment

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Exercise training, diet counseling for patients with heart disease risk improves quality of life

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

Researchers reveal new way of restraining beta-catenin to suppress tumor metastasis

Enlarged hearts regress faster in elderly women than in men after aortic valve replacement

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

New 'Therapeutic Hypothermia and Temperature Management' journal

Experts warn dip in antibiotic R&D could lead to treatment challenges

Human cytomegalovirus cloned

ADHD medication improves childhood cancer survivors: Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News